Heerlen

• Laparoscopic Antibiotic Lavage to Prevent intra-abdominal Abscess formation in Complicated Appendicitis (ALPACA) Recruiting
  2024-514850-59-00 5 2025-02-24 Appendicitis
• Safe Stop Trial Melanoma Recruiting
  2024-516937-10-01 5 2024-12-18 Melanoma
• Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting
  2024-513092-40-00 6 2024-12-05 Stroke
• The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlle … Recruiting
  2024-514055-15-00 6 2024-11-19 Pulmonary sarcoidosis
• PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized … Recruiting
  2023-504144-33-01 11 2024-10-17 esophageal cancer
• Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting
  2024-514927-40-02 11 2024-10-01 Chronic Subdural Hematoma
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• CLEAR-PATH trial Recruiting
  2024-513363-15-01 11 2024-07-22 (Chronic) Peripheral (occlusive) arterial disease (PAD)
• Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting
  2022-502968-20-02 4 2024-05-30 Behcet's disease
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• Peroperative Administration of Tranexamic acid in gastric bypass to reduce haemorrhage in patients with morbid obesity Recruiting
  2024-513570-22-00 5 2023-04-28 Morbid obesity
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P … Ended recruitment
  2024-518171-59-00 11 2025-01-23 Prostate Cancer
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended recruitment
  2024-516511-24-00 11 2024-11-14 Chronic myeloid leukaemia
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• Safe Stop ipi-nivo Ended recruitment
  2024-516938-34-00 5 2024-09-11 Melanoma

Showing 25–48 of 88 trials